PureTech Health plc, a science-driven healthcare company, focuses on developing technologies that seek to address healthcare markets. The company, through its subsidiaries and operating companies, engages in developing microbiome immune system drug-discovery platform and drug candidates for the treatment of immune-mediated diseases; and products that seek to induce weight loss and potentially enhance glycaemic control through an orally administered capsule. It is also developing technology and products for the screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric di...
501 Boylston Street
Boston, MA 02116
Founded in 2015
PureTech Health plc Appoints Joseph Bolen, Ph.D., as Chief Scientific Officer
Oct 20 16
PureTech Health plc announced the appointment of Joseph Bolen, Ph.D., as the company’s Chief Scientific Officer. In this new role, Dr. Bolen will lead the scientific development and advancement of PureTech’s pipeline and will work closely with the team and Scientific Advisory Board as the Company identifies and pursues new modalities to address significant medical needs. Dr. Bolen most recently oversaw all aspects of research and development for Moderna Therapeutics as President and Chief Scientific Officer.
PureTech Health plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016
Sep 7 16
PureTech Health plc reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported revenue of $243,000 against $10,989,000 a year ago. Operating loss was $34,562,000 against $11,606,000 a year ago. Loss before taxes was $44,463,000 against $16,966,000 a year ago. Loss for the period was $43,539,000 against $18,725,000 a year ago. Loss attributable to owners of the company was $30,004,000 against $9,905,000 a year ago. Basic and diluted loss per share was $0.13 against $0.07 a year ago. Net cash used in operating activities was $28,687,000 against $2,054,000 a year ago. Purchase of property and equipment was $2,394,000 against $2,247,000 a year ago. Adjusted operating loss was $28.6 million against $7.1 million a year ago. Adjusted loss for the period was $26.9 million against $10.9 million a year ago. The primary reason for the change in revenue relates to a $10.0 million non-refundable milestone payment Vedanta Biosciences received in the first half of 2015 as part of its collaboration with Janssen Biotech Inc. to develop and commercialize VE202.
PureTech Health plc to Report First Half, 2016 Results on Sep 07, 2016
Aug 23 16
PureTech Health plc announced that they will report first half, 2016 results on Sep 07, 2016